Ipsen presents at ASCO GI the NAPOLI 3 phase III trial of the Onivyde® regimen, which showed positive survival results in previously untreated metastatic pancreatic ductal adenocarcinoma.

The investigational Onivyde® treatment (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared to nab-paclitaxel plus gemcitabine with a manageable safety profile.

' These results represent a potential breakthrough in an aggressive and difficult-to-treat cancer' says the group.

Copyright (c) 2023 CercleFinance.com. All rights reserved.